Weekly Roundup 10 Nov 2023
Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs
…the company’s efforts to complete the phase 2 clinical development of its antibody, known as AntiBKV, which is designed to combat BK polyomavirus (BKV) infections in kidney transplant recipients. The…